Intrapleural 'outside-in' gene therapy: Therapeutics for organs of the chest via gene transfer to the pleura

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 5, 2005, Pages 440-453

  Heguy, Adriana ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

1 antitrypsin deficiency; Adeno associated virus; Adenovirus; Gene therapy; Mesothelioma; Pleura

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; ANGIOGENESIS INHIBITOR; BETA INTERFERON; CAPSID PROTEIN; CD40 LIGAND; CYTOTOXIC AGENT; GANCICLOVIR; GANCICLOVIR TRIPHOSPHATE; GENE PRODUCT; GLUCOCORTICOID; IMMUNOMODULATING AGENT; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PROTEIN BAK; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VIRUS VECTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG MUSCLE LEVEL; EARLY RESPONSE GENE; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; GENETIC DISORDER; HERPES SIMPLEX VIRUS; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG PARENCHYMA; MESOTHELIOMA; NONHUMAN; PLEURA CAVITY; PROTEIN SECRETION; REVIEW; SUICIDE GENE THERAPY; SYSTEMIC CIRCULATION; THORAX DISEASE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOLOGIC FACTORS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURA;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE;

EID: 27144444044     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Light RW: Anatomy of the pleura. In: Pleural Diseases. Fourth Edition. Light RW (Ed), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001).
2. Mae M, Crystal RG: Gene transfer to the pleural mesothelium as a strategy to deliver proteins to the lung parenchyma. Hum Gene Ther (2002) 13(12):1471-1482.
3. Strange P: Pleural diseases. In: Egan's Fundamentals of Respiratory Care. Scanlan CL, Wilkins RL, Stoller JK (Eds), Mosby Inc, Saint Louis, MO, USA (2001):475-490.
4. 1-antitrypsin. Mol Ther (2004) 10(6):1003-1010.
5. Davila RM, Crouch EC: Anatomic organization of the human pleura. Semin Respir Crit Care Med (1995) 16:261-268.
6. Wang NS: Anatomy of the pleura. Clin Chest Mad (1998) 19(2):229-240.
7. Sahn SA: State of the art. The pleura. Am Rev Respir Dis (1988) 138(1):184-234.
8. Jaurand MC, Fleury-Feith J, Bernaudin JF, Bignon J: Pleural mesothelial cells. In: The Lung: Scientific Foundations. Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, New York, NY, USA (1997):961-969.
9. Mutsaers SE: The mesothelial cell. Int J Biochem Cell Biol (2004) 36(9):9-16.
10. Rennard SI, Jaurand MC, Bignon J, Kawanami O, Ferrans VJ, Davidson J, Crystal RG: Role of pleural mesothellial cells in the production of the submesothelial connective tissue matrix of lung. Am Rev Respir Dis (1984) 130(2):267-274.
11. Ohtani O, Ohtani Y, Li RX: Phylogeny and ontogeny of the lymphatic stomata connecting the pleural and peritoneal cavities with the lymphatic system - a review. Ital J Anat Embryol (2001) 106(2 Suppl 1):251-259.
12. Miserocchi G, Negrini D: Pleural space: Pressures and fluid dynamics. In: The Lung: Scientific Foundations. Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, New York, NY, USA (1997):1217-1225.
13. Waters CM, Glucksberg MR, Depaola N, Chang J, Grotberg JB: Shear stress alters pleural mesothelial cell permeability in culture. J Appl Physiol (1996) 81(1):448-458.
14. Miserocchi G: Physiology and pathophysiology of pleural fluid turnover. Eur Respir J (1997) 10(1):219-225.
15. Light RW: Physiology of the pleural space. In: Pleural Diseases. Fourth Edition. Light RW (Ed), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001):8-20.
16. Negrini D, Fabbro MD: Subatmospheric pressure in the rabbit pleural lymphatic network. J Physiol (1999) 520(3):761-769.
17. Broaddus VC, Wiener-Kronish JP, Berthiaume Y, Staub NC: Removal of pleural liquid and protein by lymphatics in awake sheep. J Appl Physiol (1988) 64(1):384-390.
18. Broaddus VC, Araya M: Liquid and protein dynamics using a new minimally invasive pleural catheter in rabbits. J Appl Physiol (1992) 72(3):851-857.
19. Light RW: Pleural effusion due to the acquired immunodeficiency syndrome, other viruses, Mycoplasma pneumoniae and rickettsiae. In: Pleural Diseases. Fourth Edition. Light RW (Ed), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001):210-218.
20. Rossi G, Sacco O: Cells of the mesothelial space. In: The Lung: Scienfific Foundations. Second Edition. Crystal RG, West JB, Weibel ER, Barnes PJ (Eds), Lippincott-Raven Publishers, New York, NY, USA (1997):971-979.
21. Medzhitov R, Janeway CA Jr: Innate immunity: The virtues of a nonclonal system of recognition. Cell (1997) 91(3):295-298.
22. Mohammed KA, Nasreen N, Ward MJ, Mubarak KK, Rodriguez-Panadero F, Antony VB: Mycobacterium-mediated chemokine expression in pleural mesothelial cells: Role of C-C chemokines in tuberculous pleurisy. J Infect Dis (1998) 178(5):1450-1456.
23. Antony VB: Immunological mechanisms in pleural disease. Eur Respir J (2003) 21(3):539-544.
24. Hage CA, Abdul-Mohammed K, Antony VB: Pathogenesis of pleural infection. Respirology (2004) 9(1):12-15.
25. Rossi GA, Balbi B, Manca F: Tuberculous pleural effusions. Evidence for selective presence of PPD-specific T-lymphocytes at site of inflammation in the early phase of the infection. Am Rev Respir Dis (1987) 136(3):575-579.
26. 1-antitrypsin following intrapleural administration in mice with pre-existing immunity to AAV. Mol Ther (2005) 11:S197.
27. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG: Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther (2000) 2(4):376-382.
28. Tranchant I, Thompson B, Nicolazzi C, Mignet N, Scherman D: Physicochemical optimisation of plasmid delivery by cationic lipids. J Gene Med (2004) 6(Suppl 1):S24-S35.
29. Niidome T, Huang L: Gene therapy progress and prospects: Nonviral vectors. Gene Ther (2002) 9(24):1647-1652.
30. 1-antitrypsin cDNA. Am J Respir Cell Mol Biol (1995) 12(4):379-384.
31. Hackett NR, Crystal RG: Adenovirus for gene therapy. In: Gene Therapy. Smyth Templeton N, Lasic DD (Eds), Marcel Dekker Inc, New York, NY, USA (2000):17-40.
32. McConnell MJ, Imperiale MJ: Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther (2004) 15(11):1022-1033.
33. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275(5304):1320-1323.
34. Mathias P, Wickham T, Moore M, Nemerow G: Multiple adenovirus serotypes use av integrins for infection. J Virol (1994) 68(10):6811-6814.
35. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR: Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA (1997) 94(5):1645-1650.
36. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen HH, Campbell KP, Caskey CT: In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther (1996) 3(11):965-972.
37. Sterman DH, Albelda SM: Advances in the diagnosis, evaluation, and management of malignant pleural mosothelioma. Respirology (2005) 10(3):266-283.
38. Hughes RS: Malignant pleural mesothelioma. Am J Med Sci (2005) 329(1):29-44.
39. Godleski JJ: Role of asbestos in etiology of malignant pleural mesothelioma. Thorac Surg Clin (2004) 14(4):479-487.
40. Pistolesi M, Rusthoven J: Malignant pleural mesothelioma: Update, current management, and newer therapeutic strategies. Chest (2004) 126(4):1318-1329.
41. Cugell DW, Kamp DW: Asbestos and the pleura: A review. Chest (2004) 125(3):1103-1117.
42. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM, Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther (1998) 9(7):1083-1092.
43. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M, Elshami A, Gelfand K, Wilson JM, Kaiser LR, Albelda SM: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther (1998) 9(14):2121-2133.
44. Treat J, Kaiser LR, Sterman DH, Litzky L, Davis A, Wilson JM, Albelda SM: Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A phase 1 trial (BB-IND 6274). Hum Gene Ther (1996) 7(16):2047-2057.
45. Sterman DH, Molnar-Kimber K, Iyengar T, Chang M, Lanuti M, Amin KM, Pierce BK, Kang E, Treat J, Recio A, Litzky L et al: A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther (2000) 7(12):1511-1518.
46. Schwarzenberger P, Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R, Theodossiou C, Gaumer R, Summer W, Freeman SM, Kolls JK: The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study. Hum Gene Ther (1998) 9(17):2641-2649.
47. Yazawa K, Fisher WE, Brunicardi FC: Current progress in suicide gene therapy for cancer. World J Surg (2002) 26(7):783-789.
48. Spencer DM: Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther (2000) 2(4):433-440.
49. Mesnil M, Yamasaki H: Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res (2000) 60(15):3989-3999.
50. Lambright ES, Force SD, Lanuti ME, Wasfi DS, Amin KM, Albelda SM, Kaiser LR: Efficacy of repeated adenovirai suicide gene therapy in a localized murine tumor model. Ann Thorac Surg (2000) 70(6):1865-1870.
51. Lanuti M, Gao GP, Force SD, Chang MY, El Kouri C, Amin KM, Hughes JV, Wilson JM, Kaiser LR, Albelda SM: Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther (1999) 10(3):463-475.
52. Kucharczuk JC, Raper S, Elshami AA, Amin KM, Sterman DH, Wheeldon EB, Wilson JM, Litzky LA, Kaiser LR, Albelda SM: Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Hum Gene Ther (1996) 7(18):2225-2233.
53. Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA, Kaiser LR, Albelda SM: Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther (1996) 7(2):141-148.
54. Smythe WR, Hwang HC, Elshami AA, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg (1995) 222(1):78-86.
55. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Albelda SM: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol (1995) 13(1):7-16.
56. Esandi MC, van Someren GD, Vincent AJ, van Bekkum DW, Valerio D, Bout A, Noteboom JL: Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther (1997) 4(4):280-287.
57. Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M, Procopio A: Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med (2000) 5(6):591-596.
58. Pataer A, Smythe WR, Yu R, Fang B, McDonnell T, Roth JA, Swisher SG: Adenovirus-mediated bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg (2001) 121(1):61-67.
59. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA et al: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther (2000) 7(5):663-670.
60. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J et al: Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother (1998) 21(3):211-217.
61. Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, Gu J, Hoffman RM: IL-2 gene therapy of advanced lung cancer patients. Anticancer Res (1996) 16(4A):1993-1998.
62. Astoul P, Picat-Joossen D, Viallat JR, Boutin C: Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A phase II study. Cancer (1998) 83(10):2099-2104.
63. Astoul P, Bertault-Peres P, Durand A, Catalin J, Vignal F, Boutin C: Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer (1994) 73(2):308-313.
64. Astoul P, Viallat JR, Laurent JC, Brandely M, Boutin C: Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest (1993) 103(1):209-213.
65. Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM: Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg (2004) 127(1):123-130.
66. Delong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, Sterman DH, Albelda SM: Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res (2003) 63(22):7845-7852.
67. Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, Albelda SM: Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res (2001) 61(16):6201-6212.
68. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, Menard O, Mignot P, Dabouls G, Douillard JY: Intrapleural treatment with recombinant γ-interferon in early stage malignant pleural mesothelioma. Cancer (1994) 74(9):2460-2467.
69. Boutin C, Viallat JR, Van Zandwijk N, Douillard JT, Paillard JC, Guerin JC, Mignot P, Migueres J, Varlet F, Jehan A: Activity of intrapleural recombinant γ-interferon in malignant mesothelioma. Cancer (1991) 67(8):2033-2037.
70. Friedlander PL, Delaune CL, Abadie JM, Toups M, LaCour J, Marrero L, Zhong Q, Kolls JK: Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol (2003) 29(3 Pt 1):321-330.
71. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 29(6 Suppl 16):15-18.
72. Crystal RG: In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol (1999) 43(Suppl):S90-S99.
73. Kong HL, Crystal RG: Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst (1998) 90(4):273-286.
74. Glade-Bender J, Kandell JJ, Yamashiro DJ: VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther (2003) 3(2):263-276.
75. Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ: Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol (2004) 25(3):549-553.
76. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J et al: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA (2003) 100(13):7785-7790.
77. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA (2002) 99(17):11399-11404.
78. Merritt RE, Yamada RE, Wasif N, Crystal RG, Korst RJ: Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma. Ann Thorac Surg (2004) 78(3):1042-1051.
79. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ: In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg (2003) 126(1):28-38.
80. Verma IM, Weitzman MD: Gene therapy: Twenty-first century medicine. Annu Rev Biochem (2005) 74:711-738.
81. Bessis N, Garcia Cozar FJ, Boissier MC: Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther (2004) 11(Suppl 1):S10-S17.
82. Carter B: Adenoassociated viruses in gene therapy. In: Gene Therapy. Smyth Templeton N, Lasic DD (Eds), Marcel Dekker Inc, New York, NY, USA (2000):41.
83. Buning H, Nicklin SA, Perabo L, Hallek M, Baker AH: AAV-based gene transfer. Curr Opin Mol Ther (2003) 5(4):367-375.
84. Grimm D, Kay MA: From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther (2003) 3(4):281-304.
85. McCarty DM, Young SM Jr, Samulski RJ: Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet (2004) 38:819-845.
86. 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest (1989) 95(1):196-208.
87. Brantly M, Nukiwa T, Crystal RG: Molecular basis of α-1-antitrypsin deficiency. Am J Med (1988) 84(6A):13-31.
88. Berns KI, Giraud C: Biology of adeno-associated virus. Curr Top Microbiol Immunol (1996) 218:1-23.
89. Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR: Selective rep-cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol Ther (2000) 2(4):394-403.
90. Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ: High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 rep and cap, Gene Ther (1999) 6(6):986-993.
91. Grimm D, Kern A, Rittner K, Kleinschmidt JA: Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther (1998) 9(18):2745-2760.
92. Xiao X, Li J, Samulski RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 72(3):2224-2232.
93. Urabe M, Ding C, Kotin RM: Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther (2002) 13(16):1935-1943.
94. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA (2002) 99(18):11854-11859.
95. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM: Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 78(12):6381-6388.
96. Summerford C, Bartlett JS, Samulski RJ: αVβ5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5(1):78-82.
97. Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J: Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 276(23):20610-20616.
98. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA: Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 9(10):1306-1312.
99. High KA: AAV-mediated gene transfer for hemophilia. Ann NY Acad Sci (2001) 953:64-74.
100. High KA: Clinical gene transfer studies for hemophilia B. Semin Thromb Hemost (2004) 30(2):257-267.
101. Travis J, Saivesen GS: Human plasma proteinase inhibitors. Annu Rev Biochem (1983) 52:655-709.
102. 1-Antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest (1990) 85(5):1343-1352.
103. 1-antitrypsin deficiency associated with emphysema. N Engl J Med (1987) 316(17):1055-1062.
104. Wewers MD, Casolaro MA, Crystal RG: Comparison of α-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the α-1-antitrypsin phenotype null-null before and during α-1-antitrypsin augmentation therapy. Am Rev Respir Dis (1987) 135(3):539-543.
105. Hubbard RC, Crystal RG: α-1-Antitrypsin augmentation therapy for α-1-antitrypsin deficiency. Am J Med (1988) 84(6A):52-62.
106. Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR: Stable therapeutic serum levels of human α-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther (2001) 8(17):1299-1306.
107. Song S, Scott-Jorgensen M, Wang J, Poirier A, Crawford J, Campbell-Thompson M, Flotte TR: Intramuscular administration of recombinant adeno-associated virus 2 α-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: Safety and immunologic aspects. Mol Ther (2002) 6(3):329-335.
108. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ, Atkinson M, Flotte TR: Sustained secretion for human α-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA (1998) 95(24):14384-14388.
109. 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther (2004) 15(1):93-128.
110. 1-antitrypsin. Clin Sci Mol Med (1978) 55(2):139-148.
111. Driskell RA, Engelhardt JF: Current status of gene therapy for inherited lung diseases. Annu Rev Physiol (2003) 65:585-612.
112. Ferrari S, Griesenbach U, Geddes DM, Alton E: Immunological hurdles to lung gene therapy. Clin Exp Immunol (2003) 132(1):1-8.
113. Ferrari S, Geddes DM, Alton EW: Barriers to and now approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev (2002) 54(11):1373-1393.
114. Kucharczuk JC, Elshami AA, Zhang HB, Smythe WR, Hwang HC, Tomlinson JS, Amin KM, Litzky LA, Albelda SM, Kaiser LR: Pleural-based mesothelioma in immune competent rats: A model to study adenoviral gene transfer. Ann Thorac Surg (1995) 60(3):593-597.
115. Harrison LH Jr, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE: Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg (2000) 70(2):407-411.
116. 1-antitrypsin. Mol Ther (2004) 9:S128.